NEW YORK, Nov. 20, 2007 (PRIME NEWSWIRE) -- Wall Street Reporter recently conducted exclusive video interviews with Horst Zerbe, CEO of IntelGenx Technologies Corporation (OTCBB:IGXT); Geert R. Kersten, CEO of CEL-SCI Corporation (AMEX:CVM); and David C. Bupp, President and CEO of Neoprobe Corporation (OTCBB:NEOP) at the 4th Annual Acumen BioFin Rodman & Renshaw Global Healthcare Conference in New York City. The video interviews can be viewed for free at www.WallStreetReporter.com.
Horst Zerbe, CEO of IntelGenx Technologies Corporation (OTCBB:IGXT), tells us about the company's oral platform delivery technologies. The company uses their proprietary technologies to develop pharmaceutical products for its partner companies.
Highlights Include:
* IntelGenx technology's applications in a wide variety of products, including hypertension drugs and anti-depressants. * Management's plans to make the company's first FDA submission in 2008. * IntelGenx's target market, which, according to Mr. Zerbe, is currently over $20 Billion.
CEL-SCI Corporation (AMEX:CVM), another thriving pharmaceuticals company, was also featured. In reference to the company's upcoming cancer drug, CEO Geert R. Kersten tells us, "The ultimate vision is that our product will be used in combination with every first cancer treatment."
Highlights Include:
* The drug's demonstrated 33% increase in overall survival at a median of 3.5 years. * Recent clearance from the FDA and Canadian Regulators for an 800-patient Phase III clinical study in head and neck cancer. * The drug's unique strategy of boosting the immune system before chemo and radiation therapies have had a chance to weaken it.
Also featured, Neoprobe Corporation (OTCBB:NEOP) President and CEO David. C. Bupp discusses the company's two revenue-generating medical device products and two forthcoming Phase III trials.
Highlights Include:
* Neoprobe's key focus, Lymphoseek, a radiopharmaceutical to be used for lymphomatic mapping. * The estimated $200 Million global market potential for Lymphoseek. * The company's upcoming Phase III study of a tumor-specific antibody.
Wall Street Reporter (Est. 1843) is the premier source of investment information on global small-cap public companies in high-growth sectors. Through their magazines, special reports, web site, and conferences, WSR presents unique opportunities for discovering stocks before they appear on the radar of Wall Street and have become "must-attends" and "must-reads" for the "who's who" of the investment community. Visitors to their website, www.wallstreetreporter.com, can listen to and view exclusive audio and videos from an extensive library of CEO interviews, analysts roundtables, and conference webcast presentations, as well as subscribe to WSR's "Smart Money Alert" -- a weekly update of stock picks and timely market insights from top analysts and stock gurus.
These and other exclusive video interviews can be viewed at www.wallstreetreporter.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements.